Natarajan Sethuraman - Oct 28, 2021 Form 3 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Scientific Officer
Signature
/s/ Jared Cohen, as Attorney-in-fact
Stock symbol
TRDA
Transactions as of
Oct 28, 2021
Transactions value $
$0
Form type
3
Date filed
10/28/2021, 09:01 PM
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TRDA Common Stock 145K Oct 28, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TRDA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 68.3K $1.74 Direct F2
holding TRDA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 10.3K $2.10 Direct F3
holding TRDA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 96.4K $8.47 Direct F4
holding TRDA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 4.15K $12.52 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 114,006 shares of common stock and (ii) 30,756 shares of restricted common stock issued upon early exercise of stock options.
F2 25% of the shares subject to this option vested and became exercisable on March 4, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3 25% of the shares subject to this option shall vest and become exercisable on August 12, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4 25% of the shares subject to this option shall vest and become exercisable on March 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5 25% of the shares subject to this option shall vest and become exercisable on August 2, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.